Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May;20(4):116-118.
doi: 10.1080/15265161.2020.1730494.

Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions

Kathryn M Porter  1 , Anne Stevens  1   2   3 , Benjamin S Wilfond  1   2
Affiliations
Comment

Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions

Kathryn M Porter et al. Am J Bioeth. 2020 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Su Y, Guo J, Shen N, Morand EF, Yu D, and Li Z. 2016. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med 22:991–993. - PubMed
    1. Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, and Riemekasten G. 2015. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis 74:791–792. - PubMed
    1. Humrich JY, von Spee-Mayer C, Siegert E, Bertolo M, Rose A, Abdirama D, Enghard P, Stuhlmüller B, Sawitzki B, Huscher D, Hiepe F, Alexander T, Feist E, Radbruch A, Burmester GR, and Riemekasten G. 2019. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Reumatol 1: e44–54. DOI:10.1016/S2665-9913(19)30018-9. - DOI - PubMed
    1. Johnson LM, Duenas DM, and Wilfond BS. 2020. Ethical drug development for rare childhood diseases: When there are limited but promising data in adults, how to choose between safety or efficacy studies? American Journal of Bioethics. 20(4): 102–103. - PMC - PubMed
    1. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, and Mayock DE. 2008. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety. Pediatrics. 122(2): 383–391. doi: 10.1542/peds.2007-2711. - DOI - PubMed

Publication types

LinkOut - more resources